172 related articles for article (PubMed ID: 19225039)
1. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
[TBL] [Abstract][Full Text] [Related]
2. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
[TBL] [Abstract][Full Text] [Related]
3. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
4. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.
Jonker JW; Wagenaar E; van Deemter L; Gottschlich R; Bender HM; Dasenbrock J; Schinkel AH
Br J Pharmacol; 1999 May; 127(1):43-50. PubMed ID: 10369454
[TBL] [Abstract][Full Text] [Related]
5. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
6. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
[TBL] [Abstract][Full Text] [Related]
7. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
[TBL] [Abstract][Full Text] [Related]
8. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.
Doran A; Obach RS; Smith BJ; Hosea NA; Becker S; Callegari E; Chen C; Chen X; Choo E; Cianfrogna J; Cox LM; Gibbs JP; Gibbs MA; Hatch H; Hop CE; Kasman IN; Laperle J; Liu J; Liu X; Logman M; Maclin D; Nedza FM; Nelson F; Olson E; Rahematpura S; Raunig D; Rogers S; Schmidt K; Spracklin DK; Szewc M; Troutman M; Tseng E; Tu M; Van Deusen JW; Venkatakrishnan K; Walens G; Wang EQ; Wong D; Yasgar AS; Zhang C
Drug Metab Dispos; 2005 Jan; 33(1):165-74. PubMed ID: 15502009
[TBL] [Abstract][Full Text] [Related]
9. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption.
Uhr M; Steckler T; Yassouridis A; Holsboer F
Neuropsychopharmacology; 2000 Apr; 22(4):380-7. PubMed ID: 10700657
[TBL] [Abstract][Full Text] [Related]
10. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice.
Xie R; Hammarlund-Udenaes M; de Boer AG; de Lange EC
Br J Pharmacol; 1999 Oct; 128(3):563-8. PubMed ID: 10516633
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.
Nakanishi T; Karp JE; Tan M; Doyle LA; Peters T; Yang W; Wei D; Ross DD
Clin Cancer Res; 2003 Aug; 9(9):3320-8. PubMed ID: 12960118
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.
Ejsing TB; Pedersen AD; Linnet K
Hum Psychopharmacol; 2005 Oct; 20(7):493-500. PubMed ID: 16118767
[TBL] [Abstract][Full Text] [Related]
13. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
Breedveld P; Beijnen JH; Schellens JH
Trends Pharmacol Sci; 2006 Jan; 27(1):17-24. PubMed ID: 16337012
[TBL] [Abstract][Full Text] [Related]
14. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
Kivistö KT; Zukunft J; Hofmann U; Niemi M; Rekersbrink S; Schneider S; Luippold G; Schwab M; Eichelbaum M; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):124-30. PubMed ID: 15322734
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier.
Doze P; Van Waarde A; Elsinga PH; Hendrikse NH; Vaalburg W
Synapse; 2000 Apr; 36(1):66-74. PubMed ID: 10700027
[TBL] [Abstract][Full Text] [Related]
17. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
[TBL] [Abstract][Full Text] [Related]
18. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine.
Pavek P; Merino G; Wagenaar E; Bolscher E; Novotna M; Jonker JW; Schinkel AH
J Pharmacol Exp Ther; 2005 Jan; 312(1):144-52. PubMed ID: 15365089
[TBL] [Abstract][Full Text] [Related]
19. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice.
Johnson DR; Finch RA; Lin ZP; Zeiss CJ; Sartorelli AC
Cancer Res; 2001 Feb; 61(4):1469-76. PubMed ID: 11245453
[TBL] [Abstract][Full Text] [Related]
20. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
Yamazaki M; Neway WE; Ohe T; Chen I; Rowe JF; Hochman JH; Chiba M; Lin JH
J Pharmacol Exp Ther; 2001 Mar; 296(3):723-35. PubMed ID: 11181899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]